Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
13/07/2026 08:01
BRIEF-Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury July 13 (Reuters) - Newbury Pharmaceuticals AB NEWBRY.ST:
RECEIVES MARKETING AUTHORIZATION FOR TOFACITINIB NEWBURY IN SWEDEN
APPROVALS IN NORWAY AND DENMARK EXPECTED AFTER NATIONAL REVIEWS
SCANDINAVIAN MARKET FOR TOFACITINIB ESTIMATED AT 19.3 MILLION EUROS ANNUALLY
Source text: ID:nMFN2cbM86
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln